The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

NOX4/Src regulates ANP secretion through activating ERK1/2 and Akt/GATA4 signaling in beating rat hypoxic atria

  • Wu, Cheng-zhe (Department of Physiology, School of Medicine, Yanbian University) ;
  • Li, Xiang (Department of Physiology, School of Medicine, Yanbian University) ;
  • Hong, Lan (Department of Physiology, School of Medicine, Yanbian University) ;
  • Han, Zhuo-na (Department of Physiology, School of Medicine, Yanbian University) ;
  • Liu, Ying (Department of Physiology, School of Medicine, Yanbian University) ;
  • Wei, Cheng-xi (Inner Mongolia University for Nationalities) ;
  • Cui, Xun (Department of Physiology, School of Medicine, Yanbian University)
  • Received : 2020.09.11
  • Accepted : 2020.12.29
  • Published : 2021.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Nicotinamide adenine dinucleotide phosphate oxidases (NOXs) are the major enzymatic source of reactive oxygen species (ROS). NOX2 and NOX4 are expressed in the heart but its role in hypoxia-induced atrial natriuretic peptide (ANP) secretion is unclear. This study investigated the effect of NOX on ANP secretion induced by hypoxia in isolated beating rat atria. The results showed that hypoxia significantly upregulated NOX4 but not NOX2 expression, which was completely abolished by endothelin-1 (ET-1) type A and B receptor antagonists BQ123 (0.3 μM) and BQ788 (0.3 μM). ET-1-upregulated NOX4 expression was also blocked by antagonists of secreted phospholipase A2 (sPLA2; varespladib, 5.0 μM) and cytosolic PLA2 (cPLA2; CAY10650, 120.0 nM), and ET-1-induced cPLA2 expression was inhibited by varespladib under normoxia. Moreover, hypoxia-increased ANP secretion was evidently attenuated by the NOX4 antagonist GLX351322 (35.0 μM) and inhibitor of ROS N-Acetyl-D-cysteine (NAC, 15.0 mM), and hypoxia-increased production of ROS was blocked by GLX351322. In addition, hypoxia markedly upregulated Src expression, which was blocked by ET receptors, NOX4, and ROS antagonists. ET-1-increased Src expression was also inhibited by NAC under normoxia. Furthermore, hypoxia-activated extracellular signal-regulated kinase 1/2 (ERK1/2) and protein kinase B (Akt) were completely abolished by Src inhibitor 1 (1.0 μM), and hypoxia-increased GATA4 was inhibited by the ERK1/2 and Akt antagonists PD98059 (10.0 μM) and LY294002 (10.0 μM), respectively. However, hypoxia-induced ANP secretion was substantially inhibited by Src inhibitor. These results indicate that NOX4/Src modulated by ET-1 regulates ANP secretion by activating ERK1/2 and Akt/GATA4 signaling in isolated beating rat hypoxic atria.

Keywords

References

  1. Zhang Y, Murugesan P, Huang K, Cai H. NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. Nat Rev Cardiol. 2020;17:170-194. https://doi.org/10.1038/s41569-019-0260-8
  2. Zhang M, Perino A, Ghigo A, Hirsch E, Shah AM. NADPH oxidases in heart failure: poachers or gamekeepers? Antioxid Redox Signal. 2013;18:1024-1041. https://doi.org/10.1089/ars.2012.4550
  3. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245-313. https://doi.org/10.1152/physrev.00044.2005
  4. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293-296. https://doi.org/10.1161/hc0302.103712
  5. Rodino-Janeiro BK, Paradela-Dobarro B, Castineiras-Landeira MI, Raposeiras-Roubin S, Gonzalez-Juanatey JR, Alvarez E. Current status of NADPH oxidase research in cardiovascular pharmacology. Vasc Health Risk Manag. 2013;9:401-428.
  6. Cho KW, Seul KH, Ryu H, Kim SH, Koh GY. Characteristics of distension-induced release of immunoreactive atrial natriuretic peptide in isolated perfused rabbit atria. Regul Pept. 1988;22:333-345. https://doi.org/10.1016/0167-0115(88)90110-3
  7. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab. 2005;16:469-477. https://doi.org/10.1016/j.tem.2005.10.007
  8. De Vito P, Incerpi S, Pedersen JZ, Luly P. Atrial natriuretic peptide and oxidative stress. Peptides. 2010;31:1412-1419. https://doi.org/10.1016/j.peptides.2010.04.001
  9. Arjamaa O, Nikinmaa M. Hypoxia regulates the natriuretic peptide system. Int J Physiol Pathophysiol Pharmacol. 2011;3:191-201.
  10. Wang D, Gladysheva IP, Fan TH, Sullivan R, Houng AK, Reed GL. Atrial natriuretic peptide affects cardiac remodeling, function, heart failure, and survival in a mouse model of dilated cardiomyopathy. Hypertension. 2014;63:514-519. https://doi.org/10.1161/HYPERTENSIONAHA.113.02164
  11. Hong L, Xi J, Zhang Y, Tian W, Xu J, Cui X, Xu Z. Atrial natriuretic peptide prevents the mitochondrial permeability transition pore opening by inactivating glycogen synthase kinase 3β via PKG and PI3K in cardiac H9c2 cells. Eur J Pharmacol. 2012;695:13-19. https://doi.org/10.1016/j.ejphar.2012.07.053
  12. MacKay CE, Knock GA. Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease. J Physiol. 2015;593:3815-3828. https://doi.org/10.1113/jphysiol.2014.285304
  13. Li X, Han ZN, Liu Y, Hong L, Cui BR, Cui X. Endogenous ET-1 promotes ANP secretion through activation of COX2-L-PGDS-PPARγ signaling in hypoxic beating rat atria. Peptides. 2019;122:170150. https://doi.org/10.1016/j.peptides.2019.170150
  14. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A. 2010;107:15565-15570. https://doi.org/10.1073/pnas.1002178107
  15. Zhang M, Brewer AC, Schroder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, Shah AM. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A. 2010;107:18121-18126. https://doi.org/10.1073/pnas.1009700107
  16. Ruetten H, Thiemermann C. Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol. 1997;48:675-688.
  17. De Windt LJ, Willemsen PH, Popping S, Van der Vusse GJ, Reneman RS, Van Bilsen M. Cloning and cellular distribution of a group II phospholipase A2 expressed in the heart. J Mol Cell Cardiol. 1997;29:2095-2106. https://doi.org/10.1006/jmcc.1997.0444
  18. Su J, An XR, Li Q, Li XX, Cong XD, Xu M. Improvement of vascular dysfunction by argirein through inhibiting endothelial cell apoptosis associated with ET-1/Nox4 signal pathway in diabetic rats. Sci Rep. 2018;8:12620. https://doi.org/10.1038/s41598-018-30386-w
  19. Tam SW, Feng R, Lau WK, Law AC, Yeung PK, Chung SK. Endothelin type B receptor promotes cofilin rod formation and dendritic loss in neurons by inducing oxidative stress and cofilin activation. J Biol Chem. 2019;294:12495-12506. https://doi.org/10.1074/jbc.ra118.005155
  20. Gao S, Yuan K, Shah A, Kim JS, Park WH, Kim SH. Suppression of high pacing-induced ANP secretion by antioxidants in isolated rat atria. Peptides. 2011;32:2467-2473. https://doi.org/10.1016/j.peptides.2011.10.022
  21. Roskoski R Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 2015;94:9-25. https://doi.org/10.1016/j.phrs.2015.01.003
  22. Yuan Z, McCauley R, Chen-Scarabelli C, Abounit K, Stephanou A, Barry SP, Knight R, Saravolatz SF, Saravolatz LD, Ulgen BO, Scarabelli GM, Faggian G, Mazzucco A, Saravolatz L, Scarabelli TM. Activation of Src protein tyrosine kinase plays an essential role in urocortin-mediated cardioprotection. Mol Cell Endocrinol. 2010;325:1-7. https://doi.org/10.1016/j.mce.2010.04.013
  23. Zhang QL, Cui BR, Li HY, Li P, Hong L, Liu LP, Ding DZ, Cui X. MAPK and PI3K pathways regulate hypoxia-induced atrial natriuretic peptide secretion by controlling HIF-1 alpha expression in beating rabbit atria. Biochem Biophys Res Commun. 2013;438:507-512. https://doi.org/10.1016/j.bbrc.2013.07.106
  24. Hayek S, Nemer M. Cardiac natriuretic peptides: from basic discovery to clinical practice. Cardiovasc Ther. 2011;29:362-376. https://doi.org/10.1111/j.1755-5922.2010.00152.x
  25. Temsah R, Nemer M. GATA factors and transcriptional regulation of cardiac natriuretic peptide genes. Regul Pept. 2005;128:177-185. https://doi.org/10.1016/j.regpep.2004.12.026